



Istituto certificato:

ISO 9001:2008 (n° cert. 194315)

ISO 15189:2007 (n° cert. 194315/A)

SIGUCert 2009 certificato dei laboratori di citogenetica e genetica molecolare (n° cert. 004)

Inserito nell'Albo del MIUR dei laboratori di ricerca altamente qualificati (art. 14 D.M. 593/2000)

Institutional Review Board Comitato Etico

FROM:

Prof. Achille Ghidoni
Prof. Davide Vicini
Prof. Gaetano Oliva
Prof. Giampaolo Azzoni
Dott. Giuseppe Reguzzoni
Prof. Mauro Buscaglia

TO:

Dott.ssa Francesca R. Grati
Prof. Giuseppe Simoni
Principal Investigators

CC:

Prof. David Ledbetter, Emory University

DATE: **8 July, 2010**

RE: **Notification of Expedited Approval**

IRB n° 0000001

Copy Number Variation (CNV) Atlas of Human Development

This is your notification that your above referenced study was reviewed and APPROVED

under the Expedited review process. The approval is valid from **08/07/2010 until 31/12/2011**. Thereafter, continued approval is contingent upon the submission of a continuing review request that must be reviewed and approved by the IRB prior to the expiration date of this study.

A complete waiver of authorization has been granted by the TOMA Advanced Biomedical Assays S.p.A. IRB for the purpose of determining eligibility or recruiting subjects for this protocol. This waiver was reviewed and approved under the review procedure noted above. The approval is granted based on this boards determination that all criteria for waiver of authorization have been met. The PHI that may be used or disclosed for this use is limited to: Laboratory results.

Istituto certificato:

ISO 9001:2008 (n° cert. 194315)

ISO 15189:2007 (n° cert. 194315/A)

SIGUCert 2009 certificato dei laboratori di citogenetica e genetica molecolare (n° cert. 004)

Inserito nell'Albo del MIUR dei laboratori di ricerca altamente qualificati (art. 14 D.M. 593/2000)

Institutional Review Board Comitato Etico

Any reportable events (serious adverse events, breaches of confidentiality, protocol deviation or protocol violations) or issues resulting from this study should be reported immediately to the IRB and to the sponsoring agency (if any). Any amendments (changes to any portion of this research study including but not limited to protocol or informed consent changes) must have IRB approval before being implemented.


All correspondence and inquiries concerning this research study must include the IRB ID, the name of the Principal Investigator and the Study Title.

NOTE: The TOMA Advanced Biomedical Assays S.p.A. IRB expects that the PI will ensure that all other sites provide evidence of local IRB approval before contributing to the study.


Busto Arsizio VA – Italy: 08/07/2010

Sincerely,


Prof. Achille Ghidoni




Prof. Gaetano Oliva



Dott. Giuseppe Reguzzoni




Prof. Davide Vicini



Prof. Giampaolo Azzoni



Prof. Mauro Buscaglia



President TOMA Advanced Biomedical Assays S.p.A. Institutional Review Board

This letter has been digitally signed